(UroToday.com) Non-clear cell renal cell carcinoma (nccRCC) encompasses a heterogeneous group of histologies comprising ∼25% of all RCC diagnoses with worse outcomes than clear cell RCC. Cabozantinib inhibits receptor tyrosine kinases that regular tumor cell growth, angiogenesis, and immune cell function, including MET, VEGFR, and the TAM family of kinases (TYRO3, AXL, and MER). Cabozantinib is approved in the United States for the treatment of patients with advanced RCC, and in the European Union for patients with previously untreated advanced RCC of intermediate and poor-risk patients with advanced RCC previously treated with VEGF-targeted therapy. In retrospective studies, single-agent cabozantinib has demonstrated clinically meaningful benefits across all subtypes of nccRCC.1